Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2016.5969 mmr-15-01-0103 Articles Anti-proliferative activity of epigallocatechin-3-gallate and silibinin on soft tissue sarcoma cells HaratiKamran 1 BehrBjörn 1 WallnerChristoph 1 DaigelerAdrien 1 HirschTobias 1 JacobsenFrank 1 RennerMarcus 2 HaratiAli 3 LehnhardtMarcus 1 BecerikliMustafa 1 Department of Plastic Surgery, Burn Center, Hand Center, Sarcoma Reference Center, BG-University Hospital Bergmannsheil, D-44789 Bochum, Germany Institute of Pathology, University of Heidelberg, D-69120 Heidelberg, Germany Department of Neurosurgery, Klinikum Dortmund, D-44145 Dortmund, Germany Correspondence to: Dr Kamran Harati, Department of Plastic Surgery, Burn Center, Hand Center, Sarcoma Reference Center, BG-University Hospital Bergmannsheil, 1 Bürkle de la Camp-Platz, D-44789 Bochum, Germany, E-mail: kamran.harati@t-online.de 012017 28112016 15 1 103 110 24072016 26102016 Copyright: © Harati et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Disseminated soft tissue sarcomas (STS) present a therapeutic dilemma. The first-line cytostatic doxorubicin demonstrates a response rate of 30% and is not suitable for elderly patients with underlying cardiac disease, due to its cardiotoxicity. Well-tolerated alternative treatment options, particularly in palliative situations, are rare. Therefore, the present study assessed the anti-proliferative effects of the natural compounds epigallocatechin-3-gallate (EGCG), silibinin and noscapine on STS cells. A total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS-402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197). Cell proliferation and viability were analysed by 5-bromo-2′-deoxyuridine and MTT assays and real-time cell analysis (RTCA). RTCA indicated that noscapine did not exhibit any inhibitory effects. By contrast, EGCG decreased proliferation and viability of all cell lines except for the 1273 synovial sarcoma cell line. Silibinin exhibited anti-proliferative effects on all synovial sarcoma, liposarcoma and fibrosarcoma cell lines. Liposarcoma cell lines responded particularly well to EGCG while synovial sarcoma cell lines were more sensitive to silibinin. In conclusion, the green tea polyphenol EGCG and the natural flavonoid silibinin from milk thistle suppressed the proliferation and viability of liposarcoma, synovial sarcoma and fibrosarcoma cells. These compounds are therefore potential candidates as mild therapeutic options for patients that are not suitable for doxorubicin-based chemotherapy and require palliative treatment. The findings from the present study provide evidence to support in vivo trials assessing the effect of these natural compounds on solid sarcomas.

 soft tissue sarcoma synovial sarcoma liposarcoma fibrosarcoma epigallocatechin silibinin Introduction

Soft tissue sarcomas (STS) are a heterogeneous group of solid tumours arising from transformed cells of mesenchymal origin. They may occur throughout the body and represent ~1% of all adult malignancies (1). In patients with primary diagnosed STS without distant metastasis, standard treatment involves surgical resection with negative margins, typically followed by adjuvant radiation to decrease the risk of recurrence (2,3). However, almost half of all patients with STS develop distant metastases, rendering them unsuitable for surgery (4,5). If metastasis has occurred, the median survival time regardless of chemotherapeutic treatment is <12 months (6,7). A limited number of chemotherapeutic agents, including doxorubicin and ifosfamide, are effective for the treatment of metastatic STS (2). However, the response rates of these agents are poor and often do not result in significant extension of survival (8). Doxorubicin is the predominant chemotherapeutic agent used for the treatment of metastatic STS, and has a response rate of ~30% (9,10). The combination of doxorubicin and ifosfamide exhibits greater response rates compared with doxorubicin alone; however, it is associated with severe short- and long-term adverse effects, including bone marrow suppression and cardiomyopathy (11–13).

A multicentre analysis by the European Organisation for Research and Treatment of Cancer (trial 62012) on 455 patients with advanced STS indicated that an intensified combination treatment with doxorubicin and ifosfamide is not suitable for treatment of locally advanced or metastatic STS as a result of the serious adverse effects, and should therefore only be used with a view to tumour shrinkage (13). Furthermore, the versatility of doxorubicin is limited by dose-associated and cumulative myocardial toxicity, particularly in older patients with a history of cardiac disease (14). However, the incidence of STS increases markedly >50 years of age, when the prevalence of cardiac diseases is also greater (15). Currently, there are no efficacious and safe agents for the palliative treatment of patients who may not undergo doxorubicin-based chemotherapy due to underlying cardiac disease. Therefore, the development of novel therapeutic agents is required for the treatment of STS.

A review of the literature reveals various potential well-tolerated and natural phytochemicals that exhibit anti-neoplastic effects on malignant cells, including the compounds epigallocatechin-3-gallate (EGCG), silibinin and noscapine. EGCG is the most abundant catechin in green tea and demonstrates anti-inflammatory, antioxidant and antineoplastic activities (16–18). Various in vitro studies have revealed that EGCG exhibits anticancer activity in lung (19), prostate (20), colon (21), gastric (22), breast (23) and cervical carcinoma cells (24). To date, EGCG has undergone various phase II trials and has been demonstrated to be well-tolerated following oral administration (25–29). The most frequent adverse reactions observed were gastrointestinal reactions, including nausea and vomiting. In rare cases, patients presented with elevated serum alanine aminotransferase levels following the administration of high doses of oral EGCG; however, liver function tests returned to baseline following discontinuation of ECGC (30). Therefore, EGCG is considered to be a safe and well-tolerated agent for the treatment of cancer patients (31,32).

Silibinin is the primary active constituent of silymarin, a standardized extract from the seeds of the milk thistle plant (Silybum marianum). Silibinin is available as a therapeutic agent in various European countries and is used for the treatment of toxic liver damage, particularly due to Amanita phalloides intoxication (33). It is well tolerated in cancer patients (34,35) and has demonstrated anti-neoplastic effects in various malignant cell lines including HT1080 fibrosarcoma cells (36–40).

Noscapine is a naturally occurring opium alkaloid and a widely used antitussive drug that is non-addictive and has a low toxicity profile (41). As a tubulin-binding agent, various preclinical studies have established its tumour-inhibitory effects in a wide range of malignancies (42–45). Currently, noscapine is undergoing phase II clinical trials for cancer chemotherapy (46).

Based on these results, the present study aimed to investigate the anti-proliferative activity of EGCG, silibinin and noscapine on eight different STS cell lines, including fibrosarcoma, liposarcoma, synovial sarcoma and pleomorphic sarcoma cells.

 Materials and methods <sec> <title>Cell lines

Eight different human STS cell lines were used in the present study: HT1080 (fibrosarcoma), SW872 (liposarcoma), T778 (liposarcoma), MLS-402 (liposarcoma), SW982 (synovial sarcoma), SYO1 (synovial sarcoma), 1273 (synovial sarcoma) and U2197 (pleomorphic sarcoma/malignant fibrous histiocytoma). HT1080, SW872 and SW982 were purchased from CLS Cell Lines Service GmbH (Eppelheim, Germany) and were cultured in Dulbecco's modified Eagle's medium (DMEM; PAN-Biotech GmbH, Aidenbach, Germany) supplemented with 10% foetal bovine serum (FBS; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1% penicillin (100 U/ml) and 1% streptomycin (100 µg/ml; PAN-Biotech GmbH). The well-differentiated T778 liposarcoma cell line and the MLS-402 myxoid liposarcoma cell line were donated by Professor Pierre Åman (University of Gothenburg, Gothenburg, Sweden) and Professor Ola Myklebost (Oslo University Hospital, Oslo, Norway), respectively. T778 and MLS-402 cells were cultured in RPMI (PAN-Biotech GmbH) supplemented with 10% FBS and 1% penicillin/streptomycin as previously described (47,48). The SYO-1 and 1273 cell lines were donated by Dr Akira Kawai (National Cancer Center, Tokyo, Japan) and Professor Olle Larsson (Karolinska Institutet, Stockholm, Sweden) (49,50). The SYO-1 cells were cultured in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin and 0.5% sodium pyruvate. The 1273 cells were cultivated in Ham's F12 (PAN-Biotech GmbH) supplemented with 10% FBS and 1% penicillin/streptomycin. The U2197 cell line was obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and was cultured in minimum essential medium (PAN-Biotech GmbH) supplemented with 20% FBS, 0.165% sodium bicarbonate and 1% penicillin/streptomycin (51). All cultures were maintained at 37°C in a humidified 5% CO2 atmosphere.

 Phytotherapeutic agents

EGCG, silibinin and noscapine were obtained from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany). The stock solution was dissolved in dimethyl sulfoxide (DMSO; Carl Roth GmbH & Co. KG, Karlsruhe, Germany) and further diluted in DMEM to concentrations of 50 µM (EGCG), 150 µM (silibinin) and 30 µM (noscapine) for all assays. These concentrations have been demonstrated to inhibit proliferation and induce apoptosis in various malignant cell lines (36,52,53).

 Cell viability assay

Metabolic activity was measured using an MTT assay. Cells were seeded in 96-well plates (Corning Incorporated, Corning, NY, USA) at 1×104 cells per well. The following day, the three agents were added in the aforementioned concentrations for 24 h. Subsequently, 50 µl 0.5 mg/ml MTT (Sigma-Aldrich; Merck Millipore) was added for 4 h. MTT is a yellow dye that is reduced to purple formazan in the mitochondria of vital cells. Cells were lysed following the addition of 200 µl DMSO and 25 µl glycine buffer (containing 0.1 M glycine and 0.1 M NaCl, adjusted to pH 10.5 with NaOH) per well. The quantity of integrated dye represented the level of metabolism and was measured at a wavelength of 562 nm using an Elx808 Ultra Microplate Reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany).

 Proliferation assay

To quantify the effects of EGCG, silibinin and noscapine on cell proliferation, a colorimetric cell proliferation 5-bromo-2′-deoxyuridine (BrdU)-ELISA assay (Roche Diagnostics GmbH, Mannheim, Germany) was performed according to the manufacturer's protocol. Briefly, cells were seeded at 1×104 cells/well in 96-well plates and cultured for 24 h. The phytotherapeutic agents were subsequently added in the appropriate concentrations for 24 h. The BrdU labelling solution was added and incubated for a further 24 h. BrdU, a pyrimidine analogue, integrates into the DNA of proliferating cells. The level of proliferation was quantified by the light emission detected via an Orion Microplate Luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany). Cell proliferation was determined in quadruplicate. The results are expressed as a percentage of the proliferation of DMSO-treated control cells.

 Real-time cell analysis (RTCA)

Cells were seeded in two 8-well plates with an integrated microelectronic sensor array in 600 µl culture medium (iCELLigence Real Time Cell Analyser; ACEA Biosciences, San Diego, CA, USA). After 24 h, the therapeutic agents were added for a total volume of 50 µl. The cell proliferation and survival were monitored in real-time by measuring the cell-to-electrode responses of the seeded cells. In each individual E-well, the cell impedance was measured and converted to cell index (CI) values by the RTCA software version 1.2 (Roche Diagnostics GmbH) (54). The graphs were generated in real-time by the iCELLigence system. Untreated and DMSO-treated cells served as controls.

 Statistical analysis

Data analyses were performed using the statistical program SPSS 16 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation. Comparisons between the experimental groups in BrdU and MTT assays were performed using one-way analysis of variance followed by post-hoc Tukey's test. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>EGCG significantly inhibits the proliferation and viability of STS cell lines

As indicated by the BrdU assay, the proliferation of all eight human STS cell lines was inhibited by EGCG (Fig. 1). By MTT analysis, EGCG decreased the viability of seven cell lines (Fig. 2). To evaluate the proliferation and viability of cells continuously over a longer time period, RTCA was performed. The viability, adhesion and proliferation of the cells were monitored prior to and during EGCG treatment in real time for 160 h (Figs. 3–5). EGCG markedly decreased the CI of all STS cell lines except the 1273 synovial sarcoma cell line. The administration of EGCG reduced the CI of the HT1080 fibrosarcoma cell line and the U2197 pleomorphic sarcoma cell line (Fig. 3). All three liposarcoma cell lines (SW872, T778 and MLS-402) exhibited a continuously decreased CI during EGCG treatment compared with untreated or DMSO-treated cells (Fig. 4), as did the remaining two synovial sarcoma cells lines (SW982 and SYO1; Fig. 5).

 Silibinin significantly decreases the proliferative activity and viability of STS cell lines

Treatment with silibinin significantly reduced the proliferation of seven STS cell lines (Fig. 1), and significantly decreased the cell viability of all eight assessed STS cell lines, as analysed by MTT assay (Fig. 2). By RTCA, silibinin was the only compound that exhibited a strong inhibitory effect on all three synovial sarcoma cells (Fig. 5). In addition, silibinin reduced the CI of all liposarcoma cell lines; however, not to the extent of EGCG. Only the U2197 pleomorphic sarcoma cell line did not respond to silibinin treatment.

 By RTCA, STS cell lines are unaffected by noscapine treatment

Noscapine exhibited cytostatic effects on STS cells, as assessed using BrdU (Fig. 1) and MTT (Fig. 2) assays at 24 h. However, these effects could not be validated by RTCA over a longer time period. The proliferation inhibition resulting from noscapine treatment in six cell lines at 24 h did not result in a continual decrease of the CI. In all cell lines, the CI of noscapine-treated cells increased steadily and was comparable to the CI of DMSO-treated or untreated control cells during the 160 h of real-time analysis (Figs. 3–5).

 Discussion

STS are a heterogeneous group of rare mesenchymal malignancies. To date, systemic treatment options are limited following metastasis. Patients with distant metastases have a median survival time of less than one year despite systemic chemotherapy (6,7). Due to the infrequent and heterogeneous nature of STS the development of novel systemic therapeutic agents is challenging and novel chemotherapy strategies are lacking. Therefore, the development of well-tolerated and effective chemotherapeutic agents for the treatment of STS is required.

The present study assessed the cytostatic effects of the naturally occurring compounds noscapine, silibinin and EGCG on eight STS cell lines. By RTCA, noscapine did not exhibit any relevant anti-proliferative effects (Table I). In contrast, silibinin and EGCG exerted cytostatic effects in almost all examined STS cell lines, as assessed by BrdU, MTT and RTCA. Administration of EGCG decreased proliferation and viability of all liposarcoma cell lines and two synovial sarcoma cell lines for more than five days. In addition, it inhibited HT1080 fibrosarcoma and U2197 pleomorphic sarcoma cells. Of the three analysed compounds, EGCG exerted the greatest anti-proliferative activity in the three assessed liposarcoma cell lines, rendering it a potential agent of interest. Liposarcomas represent the most frequent somatic STS subtype and respond poorly to anthracycline-based chemotherapy, with well-differentiated and de-differentiated tumours exhibiting response rates of only 12 and 13%, respectively (55). Pleomorphic liposarcomas are the least responsive to chemotherapy, with a response rate of 5%, whereas myxoid liposarcomas have been revealed to be the most sensitive to chemotherapy, exhibiting response rates of 44–48% (56–58). In the present study, EGCG exhibited a distinct inhibitory effect on T778 cells from a well-differentiated liposarcoma, SW872 cells from a pleomorphic liposarcoma and MLS-402 cells from a myxoid liposarcoma. Although these findings were in vitro, they suggested a potential anti-proliferative activity of EGCG on liposarcoma cells that should be further investigated in vivo.

In comparison with EGCG, the inhibitory effect of silibinin was reduced in liposarcoma cells, but greater in synovial sarcoma cells. Silibinin significantly decreased proliferation and viability in all three synovial sarcoma cell lines. Although synovial sarcomas have typically been considered relatively chemosensitive, the European Organisation for Research and Treatment of Cancer recently reported a chemotherapy response rate of only 28% for patients with advanced synovial sarcoma (59). Therefore, there remains a requirement for alternative cytostatic agents for the treatment for synovial sarcomas, and the in vitro effects of silibinin demonstrated in the present study should be further examined in vivo.

A literature review revealed that the green tea polyphenol EGCG has further notable properties. Various in vivo studies have confirmed that EGCG mitigates doxorubicin-induced cardiotoxicity by suppressing oxidative stress (60–63). The oxygen free radical scavenging ability of EGCG has been demonstrated to protect cardiomyocytes from doxorubicin-mediated cardiotoxicity according to histopathological analysis (64). Furthermore, EGCG has been revealed to synergistically enhance the anticancer activity of doxorubicin in various in vivo studies on prostate and liver cancer (65–67). Notably, similar chemosensitizing and chemopreventive activities have been described for silibinin; in vivo studies revealed that silibinin synergistically enhances the apoptosis-inducing activity of doxorubicin and ameliorates doxorubicin-induced cardiotoxicity (68–73). Therefore, EGCG and silibinin may additionally function as chemopreventives and chemosensitizers for doxorubicin, which remains the first-line cytostatic for the systemic treatment of disseminated STS.

In conclusion, the present in vitro study demonstrated that EGCG and silibinin inhibit the proliferation and viability of liposarcoma, synovial sarcoma, fibrosarcoma and pleomorphic sarcoma cells. Liposarcoma cell lines responded particularly well to EGCG while synovial sarcoma cell lines were more sensitive to silibinin. To the best of our knowledge, this is the first study to assess the effects of EGCG and silibinin on such a wide range of STS cell lines, including liposarcoma, synovial sarcoma, fibrosarcoma and pleomorphic sarcoma cells. EGCG and silibinin are not intended to supplant doxorubicin for the treatment of patients with disseminated STS; however, they may be a potential therapeutic option for patients who require palliative treatment but are considered unsuitable for chemotherapy. The present study provides evidence to support in vivo trials to examine the effects of these natural compounds on STS.

 Acknowledgements

The present study was supported by a FoRUM grant from the Ruhr-University Bochum (Bochum, Germany; grant no. K090-15).

 References HoosALewisJJBrennanMFWeichgewebssarkome-prognostische Faktoren und multimodale TherapieDer Chirurg71787794200010.1007/s001040051137 PatrikidouADomontJCioffiALe CesneATreating soft tissue sarcomas with adjuvant chemotherapyCurr Treat Options Oncol122131201110.1007/s11864-011-0145-521384115 KaushalACitrinDThe role of radiation therapy in the management of sarcomasSurg Clin North Am88629646viii2008185147032517216 O'BrienGCCahillRABouchier-HayesDJRedmondHPCo-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanomaIr J Med Sci1751014200610.1007/BF03168992 SolomonLRCheesbroughJSBhargavaRMitsidesNHeapMGreenGDigglePObservational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysisSemin Dial25233238201210.1111/j.1525-139X.2011.00951.x21916999 KaravasilisVSeddonBMAshleySAl-MuderisOFisherCJudsonISignificant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patientsCancer11215851591200810.1002/cncr.2333218278813 BillingsleyKGLewisJJLeungDHCasperESWoodruffJMBrennanMFMultifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcomaCancer85389395199910.1002/(SICI)1097-0142(19990115)85:2<389::AID-CNCR17>3.3.CO;2-A10023707 PezziCMPollockREEvansHLLoriganJGPezziTABenjaminRSRomsdahlMMPreoperative chemotherapy for soft-tissue sarcomas of the extremitiesAnn Surg211476481199010.1097/00000658-199004000-0001521573781358035 Di PaolaDonato ENielsenOSEORTC Soft Tissue and Bone Sarcoma Group: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of CancerEur J Cancer38(Suppl 4)S138S141200211858980 NedeaEADeLaneyTFSarcoma and skin radiation oncologyHematol Oncol Clin North Am20401429200610.1016/j.hoc.2006.01.01716730300 BrodowiczTSchwameisEWidderJAmannGWiltschkeCDominkusMWindhagerRRitschlPPötterRKotzRZielinskiCCIntensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trialSarcoma4151160200010.1155/2000/126837185212952395444 FrustaciSGherlinzoniFDe PaoliABonettiMAzzarelliAComandoneAOlmiPBuonadonnaAPignattiGBarbieriEAdjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trialJ Clin Oncol1912381247200111230464 JudsonIVerweijJGelderblomHHartmannJTSchöffskiPBlayJYKerstJMSufliarskyJWhelanJHohenbergerPDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trialLancet Oncol15415423201410.1016/S1470-2045(14)70063-424618336 SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trialsCancer9728692879200310.1002/cncr.1140712767102 BurninghamZHashibeMSpectorLSchiffmanJDThe epidemiology of sarcomaClin Sarcoma Res214201210.1186/2045-3329-2-14230361643564705 JiangLTaoCHeAHeXOverexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallateWorld J Surg Oncol12383201410.1186/1477-7819-12-383255101794300611 LambertJDSangSHongJYangCSAnticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol, (−)-epigallocatechin-3-gallateJ Agric Food Chem581001610019201010.1021/jf102311t207184693045820 KalaiselviPRajashreeKBharathiPriya LPadmaVVCytoprotective effect of epigallocatechin-3-gallate against deoxynivalenol-induced toxicity through anti-oxidative and anti-inflammatory mechanisms in HT-29 cellsFood Chem Toxicol56110118201310.1016/j.fct.2013.01.04223410590 DengYTLinJKEGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrestJ Agric Food Chem591331813327201110.1021/jf204149c22082235 KobalkaAJKeckRWJankunJSynergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cellsCent Eur J Immunol40142015261551764472533 ParkIJLeeYKHwangJTKwonDYHaJParkOJGreen tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2Ann N Y Acad Sci1171538544200910.1111/j.1749-6632.2009.04698.x19723101 ParkJSKhoiPNJooYELeeYHLangSAStoeltzingOJungYDEGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cellsInt J Oncol4211201126201323337910 BraicuCGhermanCDIrimieABerindan-NeagoeIEpigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cellsJ Nanosci Nanotechnol13632637201310.1166/jnn.2013.688223646788 ZouCLiuHFeugangJMHaoZChowHHGarciaFGreen tea compound in chemoprevention of cervical cancerInt J Gynecol Cancer20617624201010.1111/IGC.0b013e3181c7ca5c206863822918290 ShanafeltTDCallTGZentCSLeisJFLaPlantBBowenDARoosMLaumannKGhoshAKLesnickCPhase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemiaCancer119363370201310.1002/cncr.27719227605873902473 de la TorreRde SolaSHernandezGFarréMPujolJRodriguezJEspadalerJMLangohrKCuenca-RoyoAPrincipeASafety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trialLancet Neurol15801810201610.1016/S1474-4422(16)30034-527302362 ZhaoHXiePLiXZhuWSunXSunXChenXXingLYuJA prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancerRadiother Oncol114351356201510.1016/j.radonc.2015.02.01425769379 TrudelDLabbéDPAraya-FariasMDoyenABazinetLDuchesneTPlanteMGrégoireJRenaudMCBachvarovDA two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancerGynecol Oncol131357361201310.1016/j.ygyno.2013.08.01923988418 DostalAMSamavatHBedellSTorkelsonCWangRSwensonKLeCWuAHUrsinGYuanJMKurzerMSThe safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: Results of the Minnesota Green Tea TrialFood Chem Toxicol832635201510.1016/j.fct.2015.05.019260513484540665 GarciaFACornelisonTNuñoTGreenspanDLByronJWHsuCHAlbertsDSChowHHResults of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasiaGynecol Oncol132377382201410.1016/j.ygyno.2013.12.034243889203955221 SinghBNShankarSSrivastavaRKGreen tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applicationsBiochem Pharmacol8218071821201110.1016/j.bcp.2011.07.093218277394082721 ShanafeltTDCallTGZentCSLaPlantBBowenDARoosMSecretoCRGhoshAKKabatBFLeeMJPhase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemiaJ Clin Oncol2738083814200910.1200/JCO.2008.21.1284194709222727287 MengsUPohlRTMitchellTLegalon® SIL: The antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningCurr Pharm Biotechnol1319641970201210.2174/138920112802273353223527313414726 FlaigTWGlodéMGustafsonDvan BokhovenATaoYWilsonSSuLJLiYHarrisonGAgarwalRA study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancerProstate70848855201020127732 FlaigTWGustafsonDLSuLJZirrolliJACrightonFHarrisonGSPiersonASAgarwalRGlodéLMA phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patientsInvest New Drugs25139146200717077998 KaurMVelmuruganBTyagiADeepGKatiyarSAgarwalCAgarwalRSilibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograftMol Cancer Ther823662374200910.1158/1535-7163.MCT-09-0304196384512728169 SinghRPAgarwalRProstate cancer chemoprevention by silibinin: Bench to bedsideMol Carcinog45436442200610.1002/mc.2022316637061 LeonIEPorroVDi VirgilioALNasoLGWilliamsPABollati-FogolínMEtcheverrySBAntiproliferative and apoptosis-inducing activity of an oxidovanadium (IV) complex with the flavonoid silibinin against osteosarcoma cellsJ Biol Inorg Chem195974201410.1007/s00775-013-1061-x24233155 VueBZhangSZhangXParisisKZhangQZhengSWangGChenQHSilibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluationsEur J Med Chem1093646201610.1016/j.ejmech.2015.12.041267489974738075 DuanWJLiQSXiaMYTashiroSOnoderaSIkejimaTSilibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathwaysBiol Pharm Bull344753201110.1248/bpb.34.4721212516 GhalyPEEl-MagdRM AbouChurchillCDTuszynskiJAWestFGA new antiproliferative noscapine analogue: Chemical synthesis and biological evaluationOncotarget740518405302016277773815130025 YangZRLiuMPengXLLeiXFZhangJXDongWGNoscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitroBiochem Biophys Res Commun421627633201210.1016/j.bbrc.2012.04.07922546556 LiSHeJLiSCaoGTangSTongQJoshiHCNoscapine induced apoptosis via downregulation of survivin in human neuroblastoma cells having wild type or null p53PloS One7e40076201210.1371/journal.pone.0040076228483703406069 Quisbert-ValenzuelaEOCalafGMApoptotic effect of noscapine in breast cancer cell linesInt J Oncol4826662674201627081867 LopusMNaikPKTaking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeuticsPharmacol Rep675662201510.1016/j.pharep.2014.09.00325560576 MukkavilliRGundalaSRYangCJadhavGRVangalaSReidMDAnejaRNoscapine recirculates enterohepatically and induces self-clearanceEur J Pharm Sci779099201510.1016/j.ejps.2015.05.026260269894516653 StratfordEWCastroRDaffinrudJSkårnMLauvrakSMuntheEMyklebostOCharacterization of liposarcoma cell lines for preclinical and biological studiesSarcoma20121486142012229112433403520 AmanPRonDMandahlNFioretosTHeimSArhedenKWillénHRydholmAMitelmanFRearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)Genes, chromosomes cancer5278285199210.1002/gcc.28700504031283316 KawaiANaitoNYoshidaAMorimotoYOuchidaMShimizuKBeppuYEstablishment and characterization of a biphasic synovial sarcoma cell line, SYO-1Cancer Lett204105113200410.1016/j.canlet.2003.09.03114744540 XieYSkyttingBNilssonGGasbarriAHaslamKBartolazziABrodinBMandahlNLarssonOSYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: A gain of function of the t(X;18)(p11.2;q11.2) translocationCancer Res6238613867200212097301 BecerikliMJacobsenFRittigAKöhneWNambiarSMirmohammadsadeghAStrickerITannapfelAWieczorekSEpplenJTGrowth rate of late passage sarcoma cells is independent of epigenetic events but dependent on the amount of chromosomal aberrationsExp Cell Res31917241731201310.1016/j.yexcr.2013.03.02323535008 KangHGJenabiJMLiuXFReynoldsCPTricheTJSorensenPHInhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cellsMol Cancer Ther913961407201010.1158/1535-7163.MCT-09-060420423994 ChouguleMBPatelARJacksonTSinghMAntitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancerPloS One6e17733201110.1371/journal.pone.0017733214236603057970 KovalOASakaevaGRFominASNushtaevaAASemenovDVKuliginaEVGulyaevaLFGerasimovAVRichterVASensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptinJ Cancer Res Ther11345351201510.4103/0973-1482.15730126148598 ItalianoAToulmondeMCioffiAPenelNIsambertNBompasEDuffaudFPatrikidouALortalBLe CesneAAdvanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survivalAnn Oncol2316011607201210.1093/annonc/mdr48522039081 ItalianoAGarbayDCioffiAMakiRGBuiBAdvanced pleomorphic liposarcomas: Clinical outcome and impact of chemotherapyAnn Oncol2322052206201210.1093/annonc/mds21922833275 JonesRLFisherCAl-MuderisOJudsonIRDifferential sensitivity of liposarcoma subtypes to chemotherapyEur J Cancer4128532860200510.1016/j.ejca.2005.07.02316289617 PatelSRBurgessMAPlagerCPapadopoulosNELinkeKABenjaminRSMyxoid liposarcoma. Experience with chemotherapyCancer7412651269199410.1002/1097-0142(19940815)74:4<1265::AID-CNCR2820740414>3.0.CO;2-X8055448 VlenterieMLitièreSRizzoEMarréaudSJudsonIGelderblomHLe CesneAWardelmannEMessiouCGronchiAvan der GraafWTOutcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entityEur J Cancer586272201610.1016/j.ejca.2016.02.00226968015 SaeedNMEl-NagaRNEl-BaklyWMAbdel-RahmanHMSalahElDin RAEl-DemerdashEEpigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic studyBiochem Pharmacol95145155201510.1016/j.bcp.2015.02.00625701654 KhanMASinghMKhanMSAhmadWNajmiAKAhmadSAlternative approach for mitigation of doxorubicin-induced cardiotoxicity using herbal agentsCurr Clin Pharmacol9288297201410.2174/157488470999914060616205323342982 ZhengJLeeHCBin SattarMMHuangYBianJSCardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injuryEur J Pharmacol6528288201110.1016/j.ejphar.2010.10.08221114975 LiWNieSXieMChenYLiCZhangHA major green tea component, (−)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal ratsJ Agric Food Chem5889778982201010.1021/jf101277t20666448 ChengTLiuJRenJHuangFOuHDingYZhangYMaRAnYLiuJShiLGreen tea catechin-based complex micelles combined with doxorubicin to overcome cardiotoxicity and multidrug resistanceTheranostics612771292201610.7150/thno.15133273757794924499 StearnsMEAmatangeloMDVarmaDSellCGoodyearSMCombination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: Inhibition of metastatic tumor growth in severe combined immunodeficiency miceAm J Pathol17731693179201010.2353/ajpath.2010.100330209717412993277 ChenLYeHLZhangGYaoWMChenXZZhangFCLiangGAutophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cellsPloS One9e85771201410.1371/journal.pone.0085771244656963897495 LiangGTangALinXLiLZhangSHuangZTangHLiQQGreen tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancerInt J Oncol37111123201020514403 SinghRPMallikarjunaGUSharmaGDhanalakshmiSTyagiAKChanDCAgarwalCAgarwalROral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistanceClin Cancer Res1086418647200410.1158/1078-0432.CCR-04-143515623648 TyagiAKAgarwalCChanDCAgarwalRSynergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cellsOncol Rep11493499200414719089 TyagiAKSinghRPAgarwalCChanDCAgarwalRSilibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosisClin Cancer Res835123519200212429642 RaškovićAStilinovićNKolarovićJVasovićVVukmirovićSMikovMThe protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in ratsMolecules1686018613201110.3390/molecules1610860121993249 ChlopcíkováSPsotováJMiketováPSimánekVChemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignansPhytother Res18107110200410.1002/ptr.141515022159 PsotováJChlopcíkováSGrambalFSimánekVUlrichováJInfluence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetinPhytother Res16(Suppl 1)S63S67200210.1002/ptr.81111933142

Effects of silibinin, ECGC and noscapine on cell proliferation. The proliferative activity of all cell lines was measured by BrdU assay. The assay was performed following 24 h of treatment with DMSO, silibinin, ECGC or noscapine. For clarity, the BrdU-labelling index of the DMSO-treated control cells was adjusted to 100 for each cell line and is not included. The indices for the different treatment groups were subsequently calculated as follows: Index treatment group i=(mean absorbance rate treatment group i ×100)/mean absorbance rate DMSO control. Data are presented as the mean ± standard deviation. −P>0.05, *P<0.05, **P<0.01 and ***P<0.001 vs. DMSO-treated control cells. EGCG, epigallocatechin-3-gallate; BrdU, 5-bromo-2′-deoxyuridine; DMSO, dimethyl sulfoxide.

Effects of silibinin, ECGC and noscapine on cell viability. The cell viability of all cell lines was measured by MTT assay. The assay was performed following 24 h of treatment with DMSO, silibinin, ECGC or noscapine. For clarity, the MTT-index of the DMSO-treated control cells was adjusted to 100 for each cell line and is not included. The indices for the different treatment groups were subsequently calculated as follows: Index treatment group i=(mean absorbance rate treatment group i ×100)/mean absorbance rate DMSO control. Data are presented as the mean ± standard deviation. −P>0.05, *P<0.05, **P<0.01 and ***P<0.001 vs. DMSO-treated control cells. EGCG, epigallocatechin-3-gallate; DMSO, dimethyl sulfoxide.

Real-time cell analysis of fibrosarcoma and malignant fibrous histiocytoma cells. (A) HT1080 fibrosarcoma cells and (B) U2197 pleomorphic sarcoma/malignant fibrous histiocytoma cells were seeded in 8-well plates with an integrated microelectronic sensor array. The CI reflecting the number of viable cells was monitored continuously in real-time. The compounds were applied to the wells after 24 h resulting in a bend of the CI curve as impedance measurements were transiently disrupted by the addition of the solutions. In EGCG-treated HT1080 cells, CI decreased and remained at a low level. Silibinin slightly decreased the CI of HT1080 cells. U2197 cells were unaffected by silibinin and responded only poorly to EGCG. EGCG, epigallocatechin-3-gallate; CI, cell index; DMSO, dimethyl sulfoxide.

Real-time cell analysis of liposarcoma cell lines. (A) SW872, (B) T778 and (C) MLS-402 liposarcoma cells were seeded in 8-well plates with an integrated microelectronic sensor array. The CI reflecting the number of viable cells was monitored continuously in real-time. The compounds were applied to the wells after 24 h resulting in a bend of the CI curve as impedance measurements were transiently disrupted by the addition of the solutions. The CI curve of SW872 cells was slightly decreased by silibinin. T778 and MLS-402 cells exhibited a moderate response to silibinin, and a strong response to EGCG. EGCG, epigallocatechin-3-gallate; CI, cell index; DMSO, dimethyl sulfoxide.

Real-time cell analysis of synovial sarcoma cell lines. (A) SW982, (B) SYO1 and (C) 1273 synovial sarcoma cells were seeded in 8-well plates with an integrated microelectronic sensor array. The CI reflecting the number of viable cells was monitored continuously in real-time. The compounds were applied to the wells after 24 h resulting in a bend of the CI curve as impedance measurements were transiently disrupted by the addition of the solutions. EGCG reduced the CI gradient of SW982 and SYO1 cells, but had no effect on 1273 cells. Silibinin markedly decreased the viability of all three synovial sarcoma cell lines. EGCG, epigallocatechin-3-gallate; CI, cell index; DMSO, dimethyl sulfoxide.

Summary of the cytostatic effects of EGCG, silibinin and noscapine, as assessed by MTT and BrdU assays and RTCA.

EGCG Silibinin Noscapine
Subtype Cell line MTT BrdU RTCA MTT BrdU RTCA MTT BrdU RTCA
Fibrosarcoma HT1080 + + + + + + + + −
Liposarcoma SW872 + + + + − + + + −
T778 + + + + + + + + −
MLS-402 + + + + + + + − −
Synovial sarcoma SW982 + + + + + + + + −
SYO1 − + + + + + + − −
1273 + + − + + + + + +
Pleomorphic sarcoma U2197 + + + + + − − + −

+, cytostatic effect; -, no cytostatic effect. EGCG, epigallocatechin-3-gallate; BrdU, 5-bromo-2′-deoxyuridine; RTCA, real-time cell analysis.